Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Astodrimer - Starpharma

Next Previous
Drug Profile

Astodrimer - Starpharma

Alternative Names: 3% w/w SPL7013 Gel; Astodrimer sodium; Betadine BV; BETADINE BV Gel; Betafem BV; BRI-7013; Fleurstat BVgel; SPL-7013; VIRALEZE; Viraleze; VivaGel; VivaGel®BV

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biomolecular Research Institute
  • Developer Aspen Pharmacare; Starpharma; The Scripps Research Institute
  • Class Antibacterials; Antivirals; Dendrimers; Peptides
  • Mechanism of Action Anion transport protein modulators; Surface antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Bacterial vaginosis; COVID 2019 infections
  • Phase I/II Herpes simplex virus infections; HIV infections
  • No development reported Conjunctivitis; Human papillomavirus infections; Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Middle East respiratory syndrome coronavirus; Respiratory syncytial virus infections; Severe acute respiratory syndrome; Zika virus infection

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for preclinical development in Influenza-A virus H3N2 subtype in USA (Intranasal, Spray)
  • 28 Apr 2025 No recent reports of development identified for preclinical development in Middle-East-respiratory-syndrome-coronavirus in USA (Intranasal, Spray)
  • 28 Apr 2025 No recent reports of development identified for preclinical development in Severe acute respiratory syndrome in USA (Intranasal, Spray)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top